Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665671 | 0.85 | KIF11 (0.55) | KIF11RNPEPFOLH1 | |
| SCHEMBL27608746 | 0.81 | KIF11 (0.78) | KIF11 | |
| SCHEMBL4397129 | 0.81 | KIF11 (0.78) | KIF11 | |
| SCHEMBL2835140 | 0.80 | KIF11 (0.53) | KIF11 | |
| SCHEMBL6512676 | 0.78 | KIF11 (0.53) | KIF11 | |
| SCHEMBL23405871 | 0.77 | KIF11 (0.43) | KIF11 | |
| SCHEMBL17502350 | 0.77 | KIF11 (0.53) | KIF11 | |
| SCHEMBL23405873 | 0.77 | KIF11 (0.48) | KIF11 | |
| SCHEMBL8346825 | 0.76 | KIF11 (0.60) | KIF11 | |
| SCHEMBL28853106 | 0.75 | MAPT (0.52) | RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736881-A2 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | Ascendis Pharma Growth Disorders A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4275677-B1 | DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| EP-4710947-A2 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | Ascendis Pharma Growth Disorders A/S (DK) | 2026-03-18 | — | — | EP | disclosed |
| EP-3400065-B1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2025-12-17 | — | — | EP | disclosed |
| US-12453778-B2 | Incremental dose finding in controlled-release PTH compounds | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2025-10-28 | — | — | US | disclosed |
| US-20250302924-A1 | Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2025-10-02 | — | — | US | disclosed |
| US-20250268988-A1 | PTH Prodrugs | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2025-08-28 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-12295989-B2 | Controlled-release PTH compound | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2025-05-13 | — | — | US | disclosed |
| EP-2459228-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | Sanofi-Aventis Deutschland GmbH (DE) | 2012-06-06 | — | — | EP | disclosed |
| EP-2459220-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2012-06-06 | — | — | EP | disclosed |
| EP-2459171-A1 | LONG ACTING INSULIN COMPOSITION | Sanofi-Aventis Deutschland GmbH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
| CN-101980725-A | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA AS | 2011-02-23 | — | — | CN | disclosed |
| WO-2011012719-A1 | LONG ACTING INSULIN COMPOSITION | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012718-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| EP-2237799-A2 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | Ascendis Pharma AS (DK) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009095479-A2 | PRODRUG COMPRISING A SELF-CLEAVABLE LINKER | ASCENDIS PHARMA AS (DK) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268988-A1 | PTH Prodrugs | PTH1R, PTMS, PHPT1 | KIF11 4271/4885RNPEP 684/4885FOLH1 136/4885 |
| US-20250302924-A1 | Controlled-Release PTH Compound | PTH1R, CALCA, CALCB | KIF11 1861/4885RNPEP 2891/4885FOLH1 1694/4885 |
| US-12453778-B2 | Incremental dose finding in controlled-release PTH compounds | PTH1R, CALCA, CALCB | KIF11 2832/4885RNPEP 3372/4885FOLH1 1672/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | KIF11 2789/4885RNPEP 1120/4885FOLH1 1979/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KIF11 3244/4885RNPEP 881/4885FOLH1 642/4885 |
| US-12295989-B2 | Controlled-release PTH compound | PTH1R, PTMS, FGF23 | KIF11 1845/4885RNPEP 2088/4885FOLH1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.